| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $5,333,139 | 35 | 100 |
| GREGORY JULIA P | director | 0 | $0 | 1 | $528,528 | $-528,528 |
| van Houte Hans | Chief Financial Officer | 0 | $0 | 7 | $669,754 | $-669,754 |
| Hansen Gwenn | Chief Scientific Officer | 0 | $0 | 10 | $757,805 | $-757,805 |
| Ring Christine | Chief Legal Officer | 0 | $0 | 18 | $3.46M | $-3.46M |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical …
Over the last 12 months, insiders at Nurix Therapeutics, Inc. have bought $0 and sold $5.33M worth of Nurix Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Nurix Therapeutics, Inc. have bought $0 and sold $2.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-11-02 | Sale | Hansen Gwenn | Chief Scientific Officer | 1,452 0.0014% | $26.80 | $38,914 | +0.47% | |
| 2026-10-30 | Sale | Hansen Gwenn | Chief Scientific Officer | 3,957 0.0035% | $26.28 | $103,986 | -3.88% | |
| 2026-10-30 | Sale | van Houte Hans | Chief Financial Officer | 2,834 0.0025% | $26.28 | $74,475 | -3.88% | |
| 2026-10-30 | Sale | Ring Christine | Chief Legal Officer | 3,957 0.0035% | $26.28 | $103,986 | -3.88% | |
| 2026-10-15 | Sale | Hansen Gwenn | Chief Scientific Officer | 1,452 0.0014% | $25.00 | $36,300 | +3.49% | |
| 2026-10-14 | Sale | GREGORY JULIA P | director | 22,583 0.0215% | $23.40 | $528,528 | +8.83% | |
| 2026-10-02 | Sale | Ring Christine | Chief Legal Officer | 5,786 0.0055% | $23.19 | $134,149 | +9.37% | |
| 2026-09-02 | Sale | Ring Christine | Chief Legal Officer | 5,787 0.0056% | $25.76 | $149,072 | -2.59% | |
| 2026-09-01 | Sale | Hansen Gwenn | Chief Scientific Officer | 1,452 0.0014% | $25.47 | $36,982 | -3.09% | |
| 2026-08-05 | Sale | Hansen Gwenn | Chief Scientific Officer | 4,356 0.0042% | $25.00 | $108,900 | +1.71% | |
| 2026-08-04 | Sale | Hansen Gwenn | Chief Scientific Officer | 4,111 0.0039% | $24.36 | $100,142 | +3.44% | |
| 2026-08-04 | Sale | van Houte Hans | Chief Financial Officer | 4,761 0.0045% | $24.36 | $115,989 | +3.44% | |
| 2026-08-03 | Sale | Ring Christine | Chief Legal Officer | 16,589 0.0148% | $23.05 | $382,358 | +9.95% | |
| 2026-07-30 | Sale | Hansen Gwenn | Chief Scientific Officer | 3,847 0.0037% | $23.38 | $89,954 | +8.23% | |
| 2026-07-30 | Sale | van Houte Hans | Chief Financial Officer | 2,845 0.0027% | $23.38 | $66,524 | +8.23% | |
| 2026-07-30 | Sale | Ring Christine | Chief Legal Officer | 3,847 0.0037% | $23.38 | $89,954 | +8.23% | |
| 2026-07-02 | Sale | Ring Christine | Chief Legal Officer | 11,008 0.0125% | $23.56 | $259,366 | +4.76% | |
| 2026-06-25 | Sale | Hansen Gwenn | Chief Scientific Officer | 5,394 0.0066% | $20.00 | $107,880 | +11.00% | |
| 2026-06-25 | Sale | Ring Christine | Chief Legal Officer | 28,935 0.0355% | $20.06 | $580,506 | +11.00% | |
| 2026-06-02 | Sale | Ring Christine | Chief Legal Officer | 8,148 0.009% | $16.60 | $135,253 | +47.53% |
| Increased Positions | 131 | +90.34% | 44M | +51.54% |
| Decreased Positions | 62 | -42.76% | 15M | -17.22% |
| New Positions | 39 | New | 16M | New |
| Sold Out Positions | 32 | Sold Out | 2M | Sold Out |
| Total Postitions | 214 | +47.59% | 114M | +34.32% |
| Fmr Llc | $160,509.00 | 8.8% | 8.89M | -2M | -14.89% | 2025-09-30 |
| Blackrock, Inc. | $122,132.00 | 6.7% | 6.76M | -46,112 | -0.68% | 2025-09-30 |
| Deep Track Capital, Lp | $109,390.00 | 6% | 6.06M | -7,886 | -0.13% | 2025-09-30 |
| Vanguard Group Inc | $81,067.00 | 4.44% | 4.49M | +23,269 | +0.52% | 2025-09-30 |
| Baker Bros. Advisors Lp | $70,111.00 | 3.84% | 3.88M | 0 | 0% | 2025-09-30 |
| Commodore Capital Lp | $68,268.00 | 3.74% | 3.78M | -168,598 | -4.27% | 2025-09-30 |
| Redmile Group, Llc | $66,432.00 | 3.64% | 3.68M | -54,494 | -1.46% | 2025-09-30 |
| Vestal Point Capital, Lp | $62,759.00 | 3.44% | 3.48M | +1M | +73.75% | 2025-09-30 |
| Point72 Asset Management, L.P. | $51,859.00 | 2.84% | 2.87M | -832,097 | -22.47% | 2025-09-30 |
| State Street Corp | $51,695.00 | 2.83% | 2.86M | +330,233 | +13.04% | 2025-09-30 |